Welcome

Sign out Have a question? We're here to help

Copyright © 2020 InvestorPlace Media, LLC. All rights reserved. 9201 Corporate Blvd, Rockville, MD 20850.

Compugen Ltd (CGEN)

$6.12 0.04 (0.66%)

17:08 EST CGEN Stock Quote Delayed 15 Minutes

Volume:

Previous Close $6.12

Market Cap 280.44M

PE Ratio -11.17

EPS -0.547999

Volume (Avg. Vol.) 297,400

Day's Range 6.01 - 6.20

52-Week Range 2.73 - 6.45

Dividend & Yield N/A (N/A)

CGEN Stock Predictions, Articles, and Compugen Ltd News

From the Web

Cantor likes Compugen in premarket analyst action

From Seeking Alpha Jan 16, 2020

Compugen (NASDAQ:CGEN) initiated with Overweight rating and $10 (73% upside) price target at Cantor Fitzgerald. Shares up 3% premarket.Diplomat Pharmacy (NYSE:DPLO) downgraded to Underperform at Credi

Stocks That Hit 52-Week Highs On Thursday

From Benzinga Jan 9, 2020

During Thursday's trading, 452 companies set new 52-week highs. Interesting Highlights: The largest company by market cap to set a new 52-week high was Morneau Shepell...

Compugen (NASDAQ:CGEN) Is In A Good Position To Deliver On Growth Plans

From Simply Wall St Jan 1, 2020

Just because a business does not make any money, does not mean that the stock will go down. By way of example, Compugen (NASDAQ:CGEN) has seen its share price rise<div><a class="permalink" href="https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-cgen/compugen/news/compugen-nasdaqcgen-is-in-a-good-position-to-deliver-on-growth-plans-2/">Read More...</a></div>

Stocks That Hit 52-Week Highs On Friday

From Benzinga Dec 27, 2019

During Friday's morning trading, 326 companies set new 52-week highs. Key Facts: Apple (NASDAQ: AAPL) was the company with the largest market cap to set a new 52-...

5 Biotech Stocks That Have More Than Doubled This Year

From Zacks Investment Research Dec 17, 2019

The biotech sector has had a good run in 2019 on the back of ongoing M&A activities and positive pipeline updates.

The Zacks Analyst Blog Highlights: ACADIA, Compugen, Cue Biopharma, Epizyme and Krystal Biotech

From Zacks Investment Research Dec 12, 2019

The Zacks Analyst Blog Highlights: ACADIA, Compugen, Cue Biopharma, Epizyme and Krystal Biotech

Navellier Ratings

Powered by Portfolio Grader

Total Grade

B

Buy